A zebrafish model of tauopathy allows in vivo imaging of neuronal cell death and drug evaluation.
Our aging society is confronted with a dramatic increase of patients suffering from tauopathies, which include Alzheimer disease and certain frontotemporal dementias. These disorders are characterized by typical neuropathological lesions including hyperphosphorylation and subsequent aggregation of TAU protein and neuronal cell death. Currently, no mechanism-based cures are available. We generated fluorescently labeled TAU transgenic zebrafish, which rapidly recapitulated key pathological features of tauopathies, including phosphorylation and conformational changes of human TAU protein, tangle formation, neuronal and behavioral disturbances, and cell death. Due to their optical transparency and small size, zebrafish larvae are well suited for both in vivo imaging and drug development. TAU-induced neuronal cell death was imaged by time-lapse microscopy in vivo. Furthermore, we used this zebrafish model to identify compounds targeting the TAU kinase glycogen synthase kinase 3beta (GSK3beta). We identified a newly developed highly active GSK3beta inhibitor, AR-534, by rational drug design. AR-534 reduced TAU phosphorylation in TAU transgenic zebrafish. This transgenic zebrafish model may become a valuable tool for further studies of the neuropathology of dementia.
Paquet
Dominik
D
Deutsches Zentrum für Neurodegenerative Erkrankungen, Munich, Germany.
Bhat
Ratan
R
Sydow
Astrid
A
Mandelkow
Eva-Maria
EM
Berg
Stefan
S
Hellberg
Sven
S
Fälting
Johanna
J
Distel
Martin
M
Köster
Reinhard W
RW
Schmid
Bettina
B
Haass
Christian
C
D000818:Animals; D030801:Animals, Genetically Modified; D016923:Cell Death; D004195:Disease Models, Animal; D015195:Drug Design; D004353:Drug Evaluation, Preclinical / Q000379:methods*; D004625:Embryo, Nonmammalian / Q000002:abnormalities / Q000187:drug effects / Q000378:metabolism / Q000473:pathology; D004791:Enzyme Inhibitors / Q000737:chemistry / Q000493:pharmacokinetics / Q000494:pharmacology; D004924:Escape Reaction; D038362:Glycogen Synthase Kinase 3 / Q000037:antagonists & inhibitors / Q000737:chemistry / Q000235:genetics; D000071679:Glycogen Synthase Kinase 3 beta; D006801:Humans; D007814:Larva / Q000033:anatomy & histology / Q000187:drug effects / Q000378:metabolism; D008164:Luminescent Proteins / Q000235:genetics / Q000378:metabolism; D008958:Models, Molecular; D015394:Molecular Structure; D009046:Motor Neurons / Q000187:drug effects / Q000378:metabolism / Q000473:pathology; D009474:Neurons / Q000187:drug effects / Q000378:metabolism / Q000473:pathology*; D010766:Phosphorylation / Q000187:drug effects; D011487:Protein Conformation; D016415:Sequence Alignment; D013116:Spinal Cord / Q000378:metabolism / Q000473:pathology; D050857:Synaptotagmins / Q000378:metabolism; D024801:Tauopathies / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology*; D015027:Zebrafish / Q000235:genetics; D016875:tau Proteins / Q000235:genetics / Q000378:metabolism; D000097573:Red Fluorescent Protein
D004791:Enzyme Inhibitors; D038362:Glycogen Synthase Kinase 3; D000071679:Glycogen Synthase Kinase 3 beta; D008164:Luminescent Proteins; D050857:Synaptotagmins; D016875:tau Proteins; D000097573:Red Fluorescent Protein; C054369:MAPT protein, human; C000605506:GSK3B protein, human